Question 1

What is hs-CRP and why do cardiologists care about it?

Accepted Answer

High-sensitivity C-reactive protein is an inflammation marker produced by the liver in response to inflammatory signaling throughout the body. The "high sensitivity" refers to the assay calibration: standard CRP tests are designed for the acute illness range of 10–100+ mg/L. The hs-CRP assay is calibrated for the 0–5 mg/L range where cardiovascular risk lives. Cardiologists care about hs-CRP because it predicts cardiovascular events independently of LDL cholesterol. In the JUPITER trial, men wit

Question 2

What's the difference between regular CRP and hs-CRP? Which one should I order?

Accepted Answer

Regular CRP and hs-CRP measure the same protein, C-reactive protein, but with assays calibrated for different ranges. Standard CRP detects meaningful elevations in acute illness, typically above 10 mg/L. The hs-CRP assay is calibrated to detect values between 0.1 and 10 mg/L with much greater precision. For cardiovascular risk assessment, the clinically meaningful range is 0.5 to 5 mg/L, entirely invisible to a standard CRP test. If you order "CRP" without specifying "high sensitivity," the lab

Question 3

My hs-CRP came back at 4.1. Is that serious?

Accepted Answer

An hs-CRP of 4.1 mg/L places you in the high cardiovascular inflammation risk category: above 3.0 mg/L is associated with approximately double the cardiovascular mortality of men below 1.0 mg/L, independent of LDL cholesterol. It is a meaningful finding that warrants a systematic investigation of its drivers, not alarm, but a structured response. What the number tells you is that something in your body is generating a sustained inflammatory signal. It does not tell you where. The cardiologist's

Question 4

What are the four main causes of elevated hs-CRP in otherwise healthy men?

Accepted Answer

The four reversible drivers of elevated hs-CRP in men who appear otherwise healthy, ranked by population prevalence in American men over 40, are: visceral fat, obstructive sleep apnea, periodontal disease, and insulin resistance. These four account for the large majority of "elevated hs-CRP with no obvious cause" seen in primary care practices. Visceral adipose tissue (the fat stored around the abdominal organs) secretes pro-inflammatory cytokines, including IL-6 and TNF-alpha, directly into the

Question 5

Does the JUPITER trial mean I should be on a statin if my hs-CRP is high even though my LDL is normal?

Accepted Answer

The JUPITER trial enrolled exactly this population, men with LDL below 130 mg/dL and hs-CRP at or above 2.0 mg/L, and found a 44% reduction in major adverse cardiovascular events with rosuvastatin. The trial was stopped early due to overwhelming benefit. So yes, elevated hs-CRP with normal-to-borderline LDL is now a recognized indication for statin consideration, and this is reflected in the current ACC/AHA guidelines, which list hs-CRP above 2.0 mg/L as a risk-enhancing factor that strengthens

Question 6

I eat a very clean anti-inflammatory diet. Why is my hs-CRP still elevated?

Accepted Answer

Because the anti-inflammatory diet claim is substantially overstated when it is not accompanied by meaningful visceral fat reduction. Dietary quality changes alone, without a change in body composition, typically reduce hs-CRP by 0.2–0.5 mg/L. A man with an hs-CRP of 4.5 who adopts a Mediterranean diet and maintains his waist circumference will likely have an hs-CRP of 4.0–4.3 mg/L six months later. This is measurable improvement, not transformation. The most powerful single lifestyle lever on h

Question 7

What is colchicine and why are cardiologists prescribing it for inflammation?

Accepted Answer

Colchicine in low-dose form (0.5 mg daily, marketed as Lodoco) received FDA approval in 2023 for cardiovascular risk reduction in patients with established atherosclerotic cardiovascular disease. It is not a supplement, it is a drug with a century of use in gout and pericarditis that was repurposed after the LoDoCo2 trial (NEJM, 2020) demonstrated a 31% reduction in major adverse cardiovascular events in patients with stable coronary artery disease. The mechanism is specific: colchicine inhibits

Question 8

Can I lower hs-CRP with supplements instead of drugs?

Accepted Answer

Supplements can lower hs-CRP modestly. The evidence-graded options are: omega-3 fatty acids at 2–4 grams per day EPA plus DHA, reducing hs-CRP by approximately 0.3–0.7 mg/L; high-dose curcumin (500–2000 mg/day of standardized extract), producing approximately 0.5–1 mg/L reduction in multiple small RCTs; and magnesium supplementation in deficient men, with modest but consistent anti-inflammatory effects. These are real effects. The clinical context matters: a man with hs-CRP of 4.5 mg/L who adds

Question 9

How often should I check my hs-CRP?

Accepted Answer

Check it once to establish your baseline as part of your cardiovascular panel, then recheck four months after you have made a specific intervention targeting one of the four drivers. hs-CRP responds to lifestyle change within eight to twelve weeks; a four-month interval gives you concrete data on whether the intervention is working. If you are on statin therapy, recheck at the three-month mark: statins reduce hs-CRP by up to 37% independent of their LDL effect (the JUPITER mechanism), and the re

Question 10

What does it mean if my hs-CRP keeps coming back elevated even after I lose weight and improve my diet?

Accepted Answer

It means you have not yet identified the driver that is maintaining the elevation. Visceral fat reduction and dietary improvement are the first two interventions for a reason, they address the most common causes. If both have been meaningfully achieved and hs-CRP remains above 2.0 mg/L on repeat testing, the three possibilities in order of clinical likelihood are: obstructive sleep apnea (present in a large proportion of men who "sleep fine"), periodontal disease (almost always asymptomatic in i

Question 11

Is inflammation the real cause of heart attacks or is it cholesterol?

Accepted Answer

The correct answer is both, operating through a specific sequence. LDL and ApoB particles are the raw material of atherosclerotic plaque: they cross the endothelial barrier, lodge in the arterial wall, and form plaque. This process is the primary driver of plaque buildup over decades. Inflammation, measured as hs-CRP and driven by the cytokines that macrophages release inside plaques, is the accelerant that determines whether a stable plaque ruptures and causes a heart attack. Think of it this w

Question 12

Can sleep apnea really raise my hs-CRP that much?

Accepted Answer

Yes. In men with severe obstructive sleep apnea, an apnea-hypopnea index above 30 events per hour, hs-CRP is chronically elevated as a consequence of nightly hypoxic stress. Every apneic event triggers a catecholamine surge and activates the NF-kB inflammatory pathway, the same pathway that drives plaque inflammation. The mechanism does not require obesity: a lean man with OSA has elevated hs-CRP even without visceral fat, because the inflammation comes directly from nightly oxygen desaturation

Question 13

What hs-CRP number means I need to see a cardiologist?

Accepted Answer

An hs-CRP consistently above 3.0 mg/L on two measurements separated by two to four weeks, with no acute illness between them, warrants a cardiovascular risk stratification conversation with a cardiologist or physician who will integrate it with your ApoB, blood pressure, family history, and other risk factors. This is the threshold where the JUPITER trial population was defined, and where the evidence for cardiovascular risk modification is most robust. If your hs-CRP is above 3.0 mg/L and you a

Question 14

Does drinking alcohol raise my hs-CRP?

Accepted Answer

Yes, dose-dependently. Alcohol raises hs-CRP through two primary mechanisms: hepatic inflammation from alcohol metabolism (acetaldehyde is directly toxic to liver cells and activates the NF-kB pathway) and gut permeability effects (chronic alcohol use increases intestinal permeability, allowing bacterial lipopolysaccharides to translocate from the gut into the portal circulation, driving systemic IL-6 production and hs-CRP elevation). The effect is proportional to dose and is not offset by the p

hs-CRP / Inflammation